Chimera Research Group

previous arrow
next arrow
Slider

March 18th Biotech Update

Not a lot of news to start the week.  Ideally we need to get some positive momentum going in the sector but there is not a ton of fundamentals to get it going this week.  It would not be bad to see the sector get some upside movement without a lot of fundamental news but […]

March 14th Biotech Update

Support held yesterday and perhaps that is an early positive sign that we have reached the bottom of this little selloff.   One day does not make a successful test of support but it was nice to see and ideally we can build on that green and even accelerate it into the end of the week. […]

March 13th Biotech Update

Well, we are no longer hanging at the higher levels and my original thought that we would test the upper end of the previous range was correct.  We are getting close and perhaps the intraday low the other day was the test, but we are pretty close.  It is probably a reasonable time to be […]

March 11th Biotech (and Oil) Update

We continue to hang out at these higher levels, although we do not seem to be able to catch any real momentum to the upside.  I think we are moving out of what is traditionally more challenging seasonality to more positive.  There is typically a post-JPM overhang as secondaries hit the sector and we have […]

Mailing List

Introduction

Overview

Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press

Slider

Log In

JoinLost Password?